ERBB2 and cancer: Lately, identification of HER2-low breast cancer has been proposed to select patients for novel HER2-directed chemotherapy and includes cancers with immunohistochemistry (IHC) 1+or 2+with negative fluorescence in situ hybridization (FISH), encompassing approximately 55–60% of all breast carcinomas.